Navigation Links
ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
Date:5/22/2008

BUENOS AIRES, Argentina, May 22 /PRNewswire-FirstCall/ -- On May 21, 2008 at the World Congress of Cardiology (WCC), the press conference entitled, "New Perspectives in Atrial Fibrillation Management" chaired by John Camm, Professor of Clinical Cardiology, St George's University of London, highlighted the importance of the newly announced ATHENA clinical trial results, on the potential management of atrial fibrillation, a common form of cardiac arrhythmia.

"ATHENA is truly a landmark trial, that marks a paradigm change for the management of atrial fibrillation," said Prof Christopher Cannon, a Senior Investigator in the TIMI Study Group at Brigham and Women's Hospital, Harvard Medical School, who was not involved in the study. "Atrial fibrillation is a very common disease, and our prior treatment options have been focused only on symptom relief and a hope to not do harm, which has been the problem with prior antiarrhythmic drugs. Now, with a highly significant reduction in cardiovascular hospitalization or death, as well as a 45% reduction in arrhythmic death or 30% cardiovascular death, dronedarone may become an appropriate treatment option for atrial fibrillation".

The ATHENA study results were presented by Prof Stefan Hohnloser last week (15th May 08) at the Heart Rhythm Society's 29th Annual Scientific Sessions in San Francisco, USA. The study results show that dronedarone significantly decreased the risk of cardiovascular hospitalizations or death from any cause by 24% (p=0.00000002), meeting the study's primary endpoint. Results of the primary endpoint were consistent across all the pre-specified clinically relevant subgroups.

The most frequently reported adverse events of Multaq(R) vs. placebo in the ATHENA trial were gastro-intestinal effects (26% vs. 22%), skin disorders (10% vs. 8%, mainly rash) and increased blood creatinine (4.7% vs. 1%). The mechanism of blood creatinine increase (inhibition of creatinine secretion at the ren
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
2. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
3. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
4. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
5. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
6. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
7. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
8. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
9. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
10. Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting
11. Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientifics SpyGlass(R) Direct Visualization System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 InVivo Therapeutics Holdings ... is revolutionizing spinal cord injury (SCI) treatment ... shown to outperform in tissue regrowth in the spinal ... Made from an FDA approved polymer, the scaffold ultimately ... harmless to the human body. NVIV has recently attracted ...
(Date:10/22/2014)... YORK , Oct. 22, 2014 Provectus ... dermatology therapies. PV-10, its novel investigational drug for cancer, ... potential for systemic side effects. Its oncology focus is ... Provectus has completed phase 2 trials of PV-10 as ... a topical treatment for atopic dermatitis and psoriasis. ...
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014   ... and WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials ... Under the terms of the collaboration, Foundation Medicine will ... of Foundation Medicine,s FoundationOne® assay at the WuXi Genome ...
Breaking Medicine Technology:InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5
... LA JOLLA, Calif. , April 28 ... industry speakers and open registration for its Wireless Health Commercialization ... part of the 5th annual WLSA Convergence Summit, a three-day ... creating value and improving health through wireless communications technologies. The ...
... The biopharma mega-mergers that grabbed headlines last year - Roche + Genentech, ... critical post-integration period and the acquiring companies are finding out how well ... verdicts, but clearly one M&A issue that continues to create problems for ... , , ...
Cached Medicine Technology:Thought Leaders Shaping the Emerging Wireless Life Science Space to Share Vision and Insights at WLSA Convergence Summit 2Thought Leaders Shaping the Emerging Wireless Life Science Space to Share Vision and Insights at WLSA Convergence Summit 3Thought Leaders Shaping the Emerging Wireless Life Science Space to Share Vision and Insights at WLSA Convergence Summit 4Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence 2Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence 3
(Date:10/22/2014)... During the Western United States’ worst ... dangerously low, Southern Oregon’s water is proving resistant to ... lowest mountain snow pack on record in 2014, remain ... autumn.* That was the observation of journalist-hikers Art Bernstein ... Southern Oregon,” during an interview with water advocate Sharon ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Losing Weight Your ... industry is staring you in the face, it certainly can ... not do your body an extra favor by doing it ... tempting crash diets. Instead, listen to your body, exercise regularly, ... Exercise is essential to losing weight; you need to exercise ...
(Date:10/22/2014)... Richard Carlson, Managing Partner of Blue ... over 25 years experience. Mr. Carlson is a ... related to EDI, B2B Commerce, RFID and Internet/Intranet technology. ... Board member for Pharmaceutical Commerce Magazine and a Gerson ... is a management and technology consulting firm focused solely ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... (IVF) are only about half as likely as white women ... research indicates, and the racial disparity persists even when donor ... of white patients became pregnant after IVF, compared to about ... IVF cycles over two years to tease out the impact ...
(Date:10/22/2014)... By Maureen Salamon ... -- A crucial part of conventional in vitro fertilization (IVF) ... can instead take place in a device inside the vagina, ... Colombia contend that the device, called an INVOcell, might sharply ... could also make the technology more accessible to those who ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... SEGUNDO, Calif., Nov. 3 DaVita Inc. (NYSE:,DVA) ... 30, 2008. Net,income for the three and nine ... $275.8 million, or $0.89 per share and $2.59 ... Net income for the three months ended September ...
... say a home safety review could cut odds of fractures ... News) -- Former first lady Nancy Reagan and Democratic ... hip injuries. And on Friday, author Studs Terkel died, following ... decline. , Such news, experts say, should be a reminder ...
... be changed , , SATURDAY, Nov. 1 (HealthDay News) -- ... according to a UCLA study of almost 1,500 patients ... and need to be treated accordingly. , The UCLA ... approach needs to be changed. , "We have shown ...
... American Academy of Otolaryngology Head and Neck ... guideline to help healthcare practitioners identify and treat ... of the most common underlying conditions that cause ... BPPV, the most common vestibular (inner ear) disorder ...
... Entrees Provide Easy, Delicious, Relief During ... Stressful Election Times, EDISON, N.J., Oct. ... isn,t much time to think about what to eat,let alone cook an ... stress with their delicious and easy gourmet,Indian cuisine that can be made ...
... wardrobe could have been spent on ... healthcare, housing, ... the http://www.DressLikePalin.com website this week, scores offering,their views on ... National Committee famously spent on the wardrobe for Gov. Sarah,Palin., ...
Cached Medicine News:Health News:DaVita 3rd Quarter 2008 Results 2Health News:DaVita 3rd Quarter 2008 Results 3Health News:DaVita 3rd Quarter 2008 Results 4Health News:DaVita 3rd Quarter 2008 Results 5Health News:DaVita 3rd Quarter 2008 Results 6Health News:DaVita 3rd Quarter 2008 Results 7Health News:DaVita 3rd Quarter 2008 Results 8Health News:DaVita 3rd Quarter 2008 Results 9Health News:DaVita 3rd Quarter 2008 Results 10Health News:DaVita 3rd Quarter 2008 Results 11Health News:DaVita 3rd Quarter 2008 Results 12Health News:DaVita 3rd Quarter 2008 Results 13Health News:DaVita 3rd Quarter 2008 Results 14Health News:DaVita 3rd Quarter 2008 Results 15Health News:DaVita 3rd Quarter 2008 Results 16Health News:DaVita 3rd Quarter 2008 Results 17Health News:Falls Are Leading Cause of Injury to Seniors 2Health News:Tailored Treatment Boosts Kidney Cancer Survival 2Health News:ENT doctors release national guideline on treatment for common cause of dizziness 2Health News:ENT doctors release national guideline on treatment for common cause of dizziness 3Health News:Easy Ethnic Election 2Health News:Tens of Thousands View DressLikePalin Web Site 2Health News:Tens of Thousands View DressLikePalin Web Site 3
Non-dissolvable Herrick Lacrimal Plugs provide long-term lacrimal occlusion through partial blockage of the horizontal canaliculus....
10 (mm) smooth platform; Serrated handle in stainless steel....
... first digital solution designed specifically for cardiologists ... outside cardiology. From the server core to ... combined expertise in both cine film and ... work the way they want, wherever they ...
... Medison SonoAce 9900 is ... based ultrasound system, with ... is DICOM compatible, designed ... general imaging, obstetrics, gynecology, ...
Medicine Products: